Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3183717 | 0.92 | AOC3 (0.60) | AOC3PTGS1PTGS2CYP3A4CYP2D6 | |
| SCHEMBL5491732 | 0.85 | AOC3 (0.65) | AOC3PTGS1PTGS2CYP3A4CYP2D6 | |
| SCHEMBL22785898 | 0.84 | AOC3 (0.64) | AOC3PTGS1PTGS2CYP3A4CYP2D6 | |
| SCHEMBL22785949 | 0.84 | AOC3 (0.64) | AOC3PTGS1PTGS2CYP3A4CYP2D6 | |
| SCHEMBL6497600 | 0.80 | PTGS1 (0.55) | AOC3PTGS1PTGS2CYP3A4CYP2D6 | |
| SCHEMBL14206671 | 0.79 | AOC3 (0.67) | AOC3PTGS1PTGS2CYP3A4CYP2D6 | |
| SCHEMBL11864310 | 0.79 | AOC3 (0.67) | AOC3PTGS1PTGS2CYP3A4CYP2D6 | |
| SCHEMBL19043557 | 0.79 | AOC3 (0.67) | AOC3PTGS1PTGS2CYP3A4CYP2D6 | |
| SCHEMBL8106605 | 0.77 | KDM4E (0.54) | AOC3PTGS1PTGS2UGCGMAPT | |
| SCHEMBL14960013 | 0.77 | AOC3 (0.52) | AOC3PTGS1PTGS2HTTUGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | AOC3 4740/4885PTGS1 1832/4885PTGS2 3234/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | AOC3 4740/4885PTGS1 1832/4885PTGS2 3234/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | AOC3 4624/4885PTGS1 1813/4885PTGS2 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.